Association between maternal thyroid function and risk of gestational hypertension and pre-eclampsia: a systematic review and individual-participant data meta-analysis

Freddy J.K. Toloza, Arash Derakhshan, Tuija Männistö, Sofie Bliddal, Polina V. Popova, David M. Carty, Liangmiao Chen, Peter Taylor, Lorena Mosso, Emily Oken, Eila Suvanto, Sachiko Itoh, Reiko Kishi, Judit Bassols, Juha Auvinen, Abel López-Bermejo, Suzanne J. Brown, Laura Boucai, Aya Hisada, Jun YoshinagaEkaterina Shilova, Elena N. Grineva, Tanja G.M. Vrijkotte, Jordi Sunyer, Ana Jiménez-Zabala, Isolina Riaño-Galan, Maria Jose Lopez-Espinosa, Larry J. Prokop, Naykky Singh Ospina, Juan P. Brito, Rene Rodriguez-Gutierrez, Erik K. Alexander, Layal Chaker, Elizabeth N. Pearce, Robin P. Peeters, Ulla Feldt-Rasmussen, Mònica Guxens, Leda Chatzi, Christian Delles, Jeanine E. Roeters van Lennep, Victor J.M. Pop, Xuemian Lu, John P. Walsh, Scott M. Nelson, Tim I.M. Korevaar, Spyridoula Maraka

Research output: Contribution to journalArticlepeer-review


Background: Adequate maternal thyroid function is important for an uncomplicated pregnancy. Although multiple observational studies have evaluated the association between thyroid dysfunction and hypertensive disorders of pregnancy, the methods and definitions of abnormalities in thyroid function tests were heterogeneous, and the results were conflicting. We aimed to examine the association between abnormalities in thyroid function tests and risk of gestational hypertension and pre-eclampsia. Methods: In this systematic review and meta-analysis of individual-participant data, we searched MEDLINE (Ovid), Embase, Scopus, and the Cochrane Database of Systematic Reviews from date of inception to Dec 27, 2019, for prospective cohort studies with data on maternal concentrations of thyroid-stimulating hormone (TSH), free thyroxine (FT4), thyroid peroxidase (TPO) antibodies, individually or in combination, as well as on gestational hypertension, pre-eclampsia, or both. We issued open invitations to study authors to participate in the Consortium on Thyroid and Pregnancy and to share the individual-participant data. We excluded participants who had pre-existing thyroid disease or multifetal pregnancy, or were taking medications that affect thyroid function. The primary outcomes were documented gestational hypertension and pre-eclampsia. Individual-participant data were analysed using logistic mixed-effects regression models adjusting for maternal age, BMI, smoking, parity, ethnicity, and gestational age at blood sampling. The study protocol was registered with PROSPERO, CRD42019128585. Findings: We identified 1539 published studies, of which 33 cohorts met the inclusion criteria and 19 cohorts were included after the authors agreed to participate. Our study population comprised 46 528 pregnant women, of whom 39 826 (85·6%) women had sufficient data (TSH and FT4 concentrations and TPO antibody status) to be classified according to their thyroid function status. Of these women, 1275 (3·2%) had subclinical hypothyroidism, 933 (2·3%) had isolated hypothyroxinaemia, 619 (1·6%) had subclinical hyperthyroidism, and 337 (0·8%) had overt hyperthyroidism. Compared with euthyroidism, subclinical hypothyroidism was associated with a higher risk of pre-eclampsia (2·1% vs 3·6%; OR 1·53 [95% CI 1·09–2·15]). Subclinical hyperthyroidism, isolated hypothyroxinaemia, or TPO antibody positivity were not associated with gestational hypertension or pre-eclampsia. In continuous analyses, both a higher and a lower TSH concentration were associated with a higher risk of pre-eclampsia (p=0·0001). FT4 concentrations were not associated with the outcomes measured. Interpretation: Compared with euthyroidism, subclinical hypothyroidism during pregnancy was associated with a higher risk of pre-eclampsia. There was a U-shaped association of TSH with pre-eclampsia. These results quantify the risks of gestational hypertension or pre-eclampsia in women with thyroid function test abnormalities, adding to the total body of evidence on the risk of adverse maternal and fetal outcomes of thyroid dysfunction during pregnancy. These findings have potential implications for defining the optimal treatment target in women treated with levothyroxine during pregnancy, which needs to be assessed in future interventional studies. Funding: Arkansas Biosciences Institute and Netherlands Organization for Scientific Research.

Original languageEnglish (US)
Pages (from-to)243-252
Number of pages10
JournalThe Lancet Diabetes and Endocrinology
Issue number4
StatePublished - Apr 2022

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Endocrinology


Dive into the research topics of 'Association between maternal thyroid function and risk of gestational hypertension and pre-eclampsia: a systematic review and individual-participant data meta-analysis'. Together they form a unique fingerprint.

Cite this